(Rac) -Clopidogrel hydrogen-d9 (sulfate)

(Rac) -Clopidogrel hydrogen-d9 sulfate is the deuterium labeled (±) -Clopidogrel (bisulfate) (HY-107867) . (±) -Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±) -Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±) -Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±) -Clopidogrel bisulfate has anti-inflammatory effects[1][2].

Product Specifications

UNSPSC

12352005

Target

Isotope-Labeled Compounds; P2Y Receptor

Related Pathways

GPCR/G Protein; Others

Field of Research

Inflammation/Immunology

Smiles

O=S(O)(O)=O.O=C(C(C1=C([2H])C([2H])=C([2H])C([2H])=C1Cl)N2CCC3=C(C([2H])=C([2H])S3)C2)OC([2H])([2H])[2H]

Molecular Formula

C16H9D9ClNO6S2

Molecular Weight

428.96

References & Citations

[1]Hagiwara S, et al. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock. 2011 Mar;35 (3) :289-92.|[2]Liu O, et al. Clopidogrel, a platelet P2Y12 receptor inhibitor, reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. PLoS One. 2012;7 (12) :e51707.